NEW YORK (GenomeWeb) – KineMed has signed a strategic deal with Pfizer to discover and develop new proteomics-based biomarkers using KineMed's protein activity kinetics tracking technology, the California-based company announced today.

Under the terms of the agreement, Pfizer has licensed KineMed's proteomics platform and the rights to discover, develop, and commercialize biomarkers. The partners will work together on discovery, while Pfizer will be responsible for developing and commercializing any biomarkers or companion diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.